Advertisement

Topics

Boehringer Ingelheim, Domain Launch CNS Drug Discovery Partnership

10:18 EST 4 Dec 2018 | Genetic Engineering News

Boehringer Ingelheim will partner with Domain Therapeutics to discover new drugs designed to treat Central Nervous System (CNS) disorders by targeting G Protein-Coupled Receptors (GPCRs), Domain said today, through a collaboration whose value was not disclosed. Also undisclosed was how many targets the companies plan to discover. Domain said the partnership will combine its expertise […]

The post Boehringer Ingelheim, Domain Launch CNS Drug Discovery Partnership appeared first on GEN - Genetic Engineering and Biotechnology News.

Original Article: Boehringer Ingelheim, Domain Launch CNS Drug Discovery Partnership

NEXT ARTICLE

More From BioPortfolio on "Boehringer Ingelheim, Domain Launch CNS Drug Discovery Partnership"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...